local_hospital

Centre Médico-Chirurgical Tronquières AURILLAC

Address
83 Avenue Charles de Gaulle, 15000 Aurillac, France

Centre Médico-Chirurgical Tronquières AURILLAC - Gastrointestinal Oncology Research

The Centre Médico-Chirurgical Tronquières in Aurillac is actively engaged in advanced gastrointestinal cancer research, participating in national cooperative group trials focused on innovative treatment strategies for challenging malignancies. The center demonstrates particular expertise in evaluating novel therapeutic approaches that combine systemic therapy, radiotherapy, and immunotherapy for locally advanced cancers.

  • Locally advanced anal squamous cell carcinoma treatment optimization through induction chemotherapy protocols
  • Neoadjuvant immunotherapy strategies for microsatellite unstable and mismatch repair-deficient rectal cancer
  • Watch-and-wait approaches combined with radiotherapy and immunotherapy for organ preservation

Through participation in PRODIGE consortium trials, the center contributes to cutting-edge research investigating chemoradiotherapy intensification strategies and organ-sparing protocols. Their involvement in phase II and III randomized trials examining dostarlimab immunotherapy combined with short-course radiotherapy, as well as modified DCF induction chemotherapy regimens, positions them at the forefront of developing personalized treatment approaches for patients with locally advanced gastrointestinal malignancies who may benefit from molecular-targeted and immune-based interventions.

Site Overview

assignment
2
connected trials
corporate_fare
2
sponsors
science
6
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
2
Total trials linked
Moderately Active
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
1
Sponsors (total)
2
Active sponsors
1

Sponsor Network

Top 1 by active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 978 other sites in France

description
Trial volume
2
Outperforms 44% of sites
public
Therapeutic diversity
1areas
Outperforms 2% of sites
groups
Sponsor diversity
2sponsors
Outperforms 45% of sites

Therapeutic Area Benchmark — France

Select a therapeutic area to compare against other sites in France.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: France

Market Share

Country: France

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Centre Médico-Chirurgical Tronquières AURILLAC

lock Showing 1 of 2 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Neoadjuvant Dostarlimab and Short-Course Radiotherapy in Microsatellite Unstable or Mismatch Repair-Deficient Locally Advanced Rectal CancerCentre Hospitalier Universitaire De DijonPhase IIRecruitingFeb 2025

IMP list

lock Showing 1 of 6 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Capecitabine1Unknown2024-02-262024-02-26

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.